A Study Evaluating the Safety, Pharmacokinetic and Anti-tumour Activity of RO7428731 in Participants With Glioblastoma

Official Title

An Open-label, Multicentre, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RO7428731 in Participants With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III


This is an open-label, multicentre study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).

Trial Description

Primary Outcome:

  • Percentage of Participants with Adverse Events (AEs)
  • Percentage of Participants with Dose Limiting Toxicities (DLTs)
Secondary Outcome:
  • Maximum Plasma Concentration (Cmax) of RO7428731
  • Time to Maximum Plasma Concentration (Tmax) of RO7428731
  • Minimum Observed Serum Concentration (Cmin) of RO7428731
  • Clearance (CL) of RO7428731
  • Half-life (t1/2) of RO7428731
  • Volume of Distribution at Steady State (Vss) of RO7428731
  • Area Under the Plasma Concentration-Time Curve (AUC) of RO7428731
  • Percentage of Participants With RO7428731 Anti-drug Antibodies (ADAs)
  • Objective Response Rate (ORR)
  • Disease Control Rate (DCR)
  • Duration of Response (DOR)
  • Progression-free Survival (PFS)
  • Overall Survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society